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UCB has been substantially limited by the low ﬁnite number
of CD34+ cells, resulting in slow hematopoietic recovery and
poor engraftment. SR1 is an aryl hydrocarbon receptor
antagonist that enables CD34 cell proliferation in the pres-
ence of SCF, Flt-3L, IL-6 and TPO. Therefore, we tested the
safety and efﬁcacy SR1-expanded UCB (referred to as
‘HSC835’). Nineteen patients (pts) with high-risk hemato-
logic malignancy have been treated with HSC835 after
myeloablative conditioning (cyclophosphamide 120 mg/kg,
ﬂudarabine 75 mg/m2 and TBI 1320 cGy) with CsA and MMF
post-transplant immune suppression. The ﬁrst 17 received
an unmanipulated second ‘back-up’ UCB unit. SR-1 expan-
sion culture yielded a median of 1,440 x 106 CD34+ cells
(range, 140.2-6361.9), a 328-fold (range, 65.9-844.0) expan-
sion of CD34+ cells, for a median infused dose of 12.3 x 106
CD34+ cells/kg (2.3-48.5). As shown (Figure), all patients
engrafted with the HSC835 unit predominating in 11/17 at a
median of 11 days for neutrophils (6-23). As expected, unit
predominance was determined by graft-graft immune re-
actions, as evidenced by the presence of interferon-g pro-
ducing T cells directed against the losing graft. Chimerism in
HSC835 engrafted patients was stable long term with no
episode of late graft failure. Compared to 111 identically
treated DUCB transplant historical controls withoutFigure. Hematopoietic Recovery Panels A and B: Rate of neutrophil and platelet rec
Comparison of CD34 cell dose and days to neutrophil recovery segregated by SR-1
transplanted with SR1 plus a companion UMN UCB unit () and those with SR-1 UCBexpanded cells (conventional arm), neutrophil and platelet
recovery was remarkably shortened in HSC835 recipients
(p<0.001 and p¼0.001, respectively). Based on these data, a
second trial with HSC835 as a stand-alone graft was initiated.
In two patients, receiving 25 and 18 x 106 CD34/kg, neutro-
phil recovery was rapid (days 12 and 8, respectively) and
complete (100% chimerism). In summary, HSC835 dramati-
cally accelerates hematopoietic recovery, abrogating the
principal barrier to the successful use of UCB. Such impres-
sive CD34+ expansion may lead to a paradigm shift for both
UCB transplantation and banking.
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A phase 3 randomized trial of transplantation of bone
marrow (BM) versus peripheral-blood (PB) stem cells from
unrelated donors showed no signiﬁcant (sig) differencesovery compared to double UCB transplant historical controls. Panels C and D:
versus unmanipulated (UMN) unit predominance. Symbols indicate patients
as a ‘stand alone’ graft (:).
Fig 1. CumI of Overall Infxns by treatment arm.
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et al, NEJM 2012;367:1487-96). Infection (infxn) was a pre-
speciﬁed secondary endpoint in this BMT CTN protocol,
sponsored by NHLBI and NCI. Moderate (mod) or more se-
vere (sev) infxns were reported on an event-driven Case
Report Form, excluding those that occurred pre-transplant.
Patients (pts) were censored at last follow up, relapse, 2nd
transplant, or 2 yrs after transplant, whichever came ﬁrst.
Among 551 pts enrolled at 48 centers between 01/2004 and
10/2009, 499 (249 of the BM arm and 250 on the PB arm) had
full audits of infxn data, accounting for 95% of transplanted
pts. Overall, 384 pts developed infxns of mod or greater
severity: 201 on the BM arm and 183 on the PB arm. Of 1347
infectious episodes (373 sev and 123 life-threatening/fatal
[LT/F]), 710 (53%) occurred on the BM arm and 637 (47%) on
the PB arm. Cumulative incidence (CumI) described the
proportion of pts developing at least one infxn, while
multivariate analyses examined the density of infxn epi-
sodes. Gray’s test for the CumI rates of infxns had p-value
0.013, with 2-yr rate 84.7% (95% conﬁdence interval [CI]:
79.6%, 89.8%) for the BM arm, vs. 79.7% (95%CI: 73.9%, 85.5%)
for the PB arm (Fig 1). Among 810 bacterial infxn episodes,
431 were on the BM arm and 379 on the PB arm, with a 2-yr
CumI of 72.1% and 62.9% respectively (Fig 2, p¼0.003). Of
these, 413 were bacterial bloodstream, 123 ClostridiumFig 2. CumI of Bacterial Infxns by treatment arm.difﬁcile, and 2 atypical mycobacterial infxns; these cate-
gories are not mutually exclusive. The Day 100 CumI of
bloodstream bacterial infxns was 44.8% (95%CI: 38.5%, 51.1%)
for the BM arm vs. 35.0% (95%CI: 28.9%, 41.1%) for the PB arm
(p¼0.027), possibly related to quicker neutrophil engraft-
ment using PB.
Infxn density was calculated as (# infxn events/100 pt days at
risk). The total infxn density was 0.67 for BM and 0.60 for PB
(P¼NS). The infxn density of bacterial infxns was 0.4 for both
arms. The infxn density for viral infxns was 0.2 in both arms.
The 2-yr CumI of CMVwas 25.9% (95%CI: 20.2%, 31.6%) for the
BM arm, vs. 24.4% (95%CI: 18.8%, 30.0%) for the PB arm
(p¼0.62). The infxn density for fungal/parasitic infxns was
0.04 and 0.05 for the BM arm and the PB arm, respectively.
The 2-yr CumI of 20 cases of aspergillosis was 3.9% (95%CI:
1.2%, 6.6%) for the BM arm, vs. 3.6% (95%CI: 1.0%, 6.2%) for the
PB arm (p¼0.811). The ongoingmorbidity andmortality from
infxns following transplantation remain frequent using
either graft source, with no observed differences in fungal or
viral infxn rates. The higher observed risks of bacterial infxns
using BM grafts may suggest either augmented prophylaxis
or heightened surveillance after these transplants.AUTOLOGOUS TRANSPLANTS
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Background: The likelihood of successful mobilization has
improved with the addition of Plerixafor to G-CSF in ASCT.
Due to its high cost, risk adapted algorithms were instituted
to identify patients who would beneﬁt from plerixafor.
Methods: The current algorithmwas instituted in December
2009. Mobilization commences with GCSF alone; plerixafor
is added if day 4 PBCD34 is<10/mL for single transplant,<20/
mL for multiple transplants, day 1 yield is <1.5 million CD34/
kg, or subsequent yield is < 0.5 million CD34/kg. Goal of
collection varied by disease and by number of intended
transplants (3-5 million CD34/kg/transplant). The results of
this mobilization strategy are presented here.
Results: We studied 1080 mobilizations in 1068 patients
using the current protocol between June 2010 and December
2013; 548MM (50%), 327 NHL (30%), 144 amyloidosis or light
chain deposition disease (AL/LCD; 13%) and 61 Hodgkin’s
(13%). Overall, 55.4% of patients required plerixafor (MM58%,
NHL 61%, AL/LCD 35%, HL 46%). The majority of patients
initiated plerixafor on day 4 for low PB CD34 count; 19%
started beyond 4 days for suboptimal CD34 collection. There
was no difference between the diagnoses in terms of the
need to initiate plerixafor for low PB CD34 or for suboptimal
CD34 collection. Median days of plerixafor was 2 (IQR 1-3);
42% and 22% required > 2 days and > 3 days, respectively.
